Correction of Vitamin D Deficiency in Chronic Hepatitis C Patients who Had Sustained Virologic Response After Direct-acting Agent Therapy : Effect on Serum Hepatic Fibrogenesis Markers

Not Applicable

Completed

• Conditions: Chronic hepatitis CLiver fibrosis; Vitamin D; Liver fibrosis; Chronic hepatitis C; TGF- β1

• Registration Number: TCTR20171206003
• Lead Sponsor: The Gastroenterological Association of Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-12-06
• Study Completion: 2018-04-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Age 18 years
Chronic hepatitis C with sustained virologic response after direct-acting agent
Evidence of liver fibrosis from fibroscan, MRE or ultrasound

Exclusion Criteria

Decompensated liver cirrhosis
Chronic liver disease or cirrhosis from other causes
HIV infection, autoimmune disease, malignancy, asthma or COPD
Pregnancy and/or lactation woman
Active viral or bacterial infection
History of steroids or immunosuppressive therapy in 6 months before enrollment
History of interferons-based therapy within 1 year
History of active alcohol drinking in 6 months before enrollment
Chronic kidney disease (GFR ≤ 60 ml/min)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change of TGFbeta1 6 weeks ng/ml

Secondary Outcome Measures

Name	Time	Method
change of TIMP1, MMP2, MMP9 6 weeks ng/ml